Abstract
Ecotropic viral integration site-1 (EVI1) is one of the candidate oncogenes for human acute myeloid leukemia (AML) with chromosomal alterations at 3q26. High EVI1 expression (EVI1high) is a risk factor for AML with poor outcome. Using DNA microarray analysis, we previously identified that integrin α6 (ITGA6) was upregulated over 10-fold in EVI1high leukemia cells. In this study, we determined whether the increased expression of ITGA6 is associated with drug-resistance and increased cell adhesion, resulting in poor prognosis. To this end, we first confirmed the expression pattern of a series of integrin genes using semi-quantitative PCR and fluorescence-activated cell sorter (FACS) analysis and determined the cell adhesion ability in EVI1high leukemia cells. We found that the adhesion ability of EVI1high leukemia cells to laminin increased with the increased expression of ITGA6 and integrin β4 (ITGB4). The introduction of small-hairpin RNA against EVI1 (shEVI1) into EVI1high leukemia cells reduced the cell adhesion ability and downregulated the expression of ITGA6 and ITGB4. In addition, the overexpression of EVI1 in EVI1low leukemia cells enhanced their cell adhesion ability and increased the expression of ITGA6 and ITGB4. In a subsequent experiment, the introduction of shRNA against ITGA6 or ITGB4 into EVI1high AML cells downregulated their cell adhesion ability; however, the EVI1high AML cells transfected with shRNA against ITGA6 could not be maintained in culture. Moreover, treating EVI1high leukemia cells with neutralizing antibodies against ITGA6 or ITGB4 resulted in an enhanced responsiveness to anti-cancer drugs and a reduction of their cell adhesion ability. The expression of ITGA6 is significantly elevated in cells from relapsed and EVI1high AML cases; therefore, ITGA6 might represent an important therapeutic target for both refractory and EVI1high AML.
Highlights
Ecotropic viral integration site-1 (EVI1) is an oncogenic transcription factor for murine and human myeloid leukemia [1,2]
EVI1 has been reported to transcriptionally repress or suppress TGFb signaling by recruiting Smad3 and the co-repressor C-terminal binding protein (CtBP) [8,9,10], we showed that EVI1 is directly associated with the GATA-2 promoter and upregulates GATA-2 transcription to maintain hematopoietic stem cells (HSCs) and acute myeloid leukemia (AML) with EVI1high expression [11,12] in EVI1deficient mice
Overexpression of integrin a6 (ITGA6) enhances the ability of EVI1high leukemia cell lines to adhere to matrigel and laminin To search for novel molecular targets in refractory myeloid leukemia with high EVI1 expression, we previously analyzed the gene expression profiles of 12 human myeloid cell lines using an oligonucleotide microarray (Human Genome U133 Plus 2.0 Array; Affymetrix) containing 38,500 genes [24]
Summary
Ecotropic viral integration site-1 (EVI1) is an oncogenic transcription factor for murine and human myeloid leukemia [1,2]. In addition to the observed reduction in GATA-2 expression, other important factors for HSC maintenance, including Angiopoietin-1 and Tie-2, were de-regulated in EVI1-deficient mice [11]. These results suggest that murine Evi might de-regulate transcription factors or other signal transduction molecules necessary for HSC maintenance [11]. The pSIREN-retroQ-ZsGreen plasmid (Takara-Bio) was used to inhibit EVI1 expression, and expression of ZsGreen (green fluorescent protein) was used as a marker. The reduction of EVI1 or ITGB4 expression was confirmed using RT-PCR
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.